(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $7.22
発行日: 15 2月 2024 @ 05:45
リターン: 20.86%
前回のシグナル: 2月 14 - 04:34
前回のシグナル:
リターン: 12.56 %
Live Chart Being Loaded With Signals
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others...
Stats | |
---|---|
本日の出来高 | 1.59M |
平均出来高 | 2.01M |
時価総額 | 1.92B |
EPS | $0 ( 2024-03-21 ) |
次の収益日 | ( $-0.300 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.97 |
ATR14 | $0.0150 (0.17%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Bishop Hans Edgar | Buy | 2 774 | Common Stock |
2024-04-01 | Fmr Llc | Buy | 0 | Common Stock |
2024-03-08 | Yang Patrick Y | Sell | 25 000 | Common Stock |
2024-03-07 | Williams Douglas E | Buy | 301 875 | Stock Option (Right to Buy) |
2024-03-07 | Williams Douglas E | Buy | 67 083 | Restricted Stock Units |
INSIDER POWER |
---|
6.23 |
Last 97 transactions |
Buy: 15 455 910 | Sell: 11 982 863 |
ボリューム 相関
Sana Biotechnology, Inc. 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Sana Biotechnology, Inc. 相関 - 通貨/商品
Sana Biotechnology, Inc. 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-30.87M (0.00 %) |
EPS: | $-1.460 |
FY | 2023 |
収益: | $0 |
総利益: | $-30.87M (0.00 %) |
EPS: | $-1.460 |
FY | 2022 |
収益: | $0 |
総利益: | $-27.73M (0.00 %) |
EPS: | $-1.410 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.958 |
Financial Reports:
No articles found.
Sana Biotechnology, Inc.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。